NCT00525616.

Trial name or title	Assessment of rituximab efficiency and tolerance in treatment of bullous pemphigoid
Methods	Non‐randomised, open label, uncontrolled, single group assignment, safety/efficacy study
Participants	20 participants with bullous pemphigoid
Interventions	2 IV perfusions of 1000 mg at 15 day intervals
Outcomes	Primary outcomes: Clinical and biological controls of bullous pemphigoid were estimated every 7 days during a period of 1 month and every month during a period of 2 years (time frame: 2 years) (designated as safety issue: yes) Secondary outcomes: Adverse reactions will be estimated during all the period of this clinical trial (time frame: 3 years) (designated as safety issue: yes)
Starting date	December 2008
Contact information	Pascal Joly, MD, PhD (pascal.joly@chu‐rouen.fr) Rouen University Hospital Direction de la Recherche et de l'Innovation Rouen 76031 France
Notes	pascal.joly@chu‐rouen.fr